1-9 of 9
Richard Furman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 1 Dose Escalation and Cohort Expansion Study of the Anti-ROR1 Antibody-Drug Conjugate Zilovertamab Vedotin (MK-2140) for the Treatment of Non-Hodgkin Lymphoma

Michael Wang, Matthew Mei, Paul M. Barr, Jacqueline Barrientos, Sven de Vos, Richard Furman, Krish Patel, Philip A. Thompson, Michael Choi, Avyakta Kallam, Ying Zhu, Samhita Chakraborty, Patricia Marinello, Stephen E. Spurgeon
Journal: Blood
Blood (2021) 138 (Supplement 1): 528.
https://doi.org/10.1182/blood-2021-148607
Published: 2021
Journal Articles

Awareness, Knowledge, and Preferences of United States (US) Patients with Chronic Lymphocytic Leukemia (CLL) and Their Caregivers Related to Finite Duration (FD) Therapy and Minimal (Measurable) Residual Disease (MRD)

Dr. Brian Koffman, Chris Stewart, Liza Avruch, Neil Bailey, Robyn Brumble, John C. Byrd, Alexey V. Danilov, Matthew S. Davids, Richard Furman, Nitin Jain, Neil E. Kay, Nicole Lamanna, Anthony R. Mato, Alan Skarbnik, Chaitra S. Ujjani, John M. Pagel
Journal: Blood
Blood (2021) 138 (Supplement 1): 1927.
https://doi.org/10.1182/blood-2021-145046
Published: 2021
Journal Articles

Novel Mechanisms of Acalabrutinib Resistance in Patients with Chronic Lymphocytic Leukemia By Whole Genome Methylome Sequencing

Kathleen Burke, Barrett Nuttall, Daniel L. Karl, Megan Callahan, Kerrin Mendler, Steven Criscione, Sergey Naumenko, Elena Bibikova, Andrew Bloecher, Brian Dougherty, J. Carl Barrett, Maurizio Scaltriti, Pablo Cingolani, John C. Byrd, Richard Furman, Jennifer R. Brown, Andrew Mortlock, James Hadfield, Veerendra Munugalavadla
Journal: Blood
Blood (2021) 138 (Supplement 1): 4361.
https://doi.org/10.1182/blood-2021-147113
Published: 2021
Journal Articles

The Tigit/CD226/CD155 Immunomodulatory Axis Is Deregulated in CLL and Contributes to B-Cell Anergy

Francesca Arruga, Andrea Iannello, Nikolaos Ioannou, Alberto Maria Todesco, Marta Coscia, Riccardo Moia, Gianluca Gaidano, John N. Allan, Richard Furman, Tiziana Vaisitti, Alan G. Ramsay, Silvia Deaglio
Journal: Blood
Blood (2021) 138 (Supplement 1): 3718.
https://doi.org/10.1182/blood-2021-150183
Published: 2021
Journal Articles

Characterization of Bruton Tyrosine Kinase Inhibitor (BTKi)-Related Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL)

John F. Seymour, John C. Byrd, Peter Hillmen, Paolo Ghia, Arnon P. Kater, Asher Chanan-Khan, Richard Furman, Susan M. O'Brien, Jennifer R Brown, Anthony R. Mato, Stephan Stilgenbauer, Nataliya Kuptsova-Clarkson, Paulo Miranda, Dennis Wagner, Kara Higgins, Sophia Sohoni, Wojciech Jurczak
Journal: Blood
Blood (2021) 138 (Supplement 1): 3721.
https://doi.org/10.1182/blood-2021-146228
Published: 2021
Journal Articles

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

Jason A. Dubovsky, Kyle A. Beckwith, Gayathri Natarajan, Jennifer A. Woyach, Samantha Jaglowski, Yiming Zhong, Joshua D. Hessler, Ta-Ming Liu, Betty Y. Chang, Karilyn M. Larkin, Matthew R. Stefanovski, Danielle L. Chappell, Frank W. Frissora, Lisa L. Smith, Kelly A. Smucker, Joseph M. Flynn, Jeffrey A. Jones, Leslie A. Andritsos, Kami Maddocks, Amy M. Lehman, Richard Furman, Jeff Sharman, Anjali Mishra, Michael A. Caligiuri, Abhay R. Satoskar, Joseph J. Buggy, Natarajan Muthusamy, Amy J. Johnson, John C. Byrd
Journal: Blood
Blood (2013) 122 (15): 2539–2549.
https://doi.org/10.1182/blood-2013-06-507947
Published: 2013
Includes: Supplemental data
Journal Articles

Targeting Early Events of B-Cell Receptor Signaling in Chronic Lymphocytic Leukemia: Suppressed Syk and PLCγ2 Activities Predict Apoptotic Response of Leukemic Cells to Dasatinib

Y. Lynn Wang, MD, PhD, Zibo Song, Pin Lu, John P. Leonard, Morton Coleman, Peter Martin, Chaowei Wu, Francis Y. Lee, Daniel M. Knowles, Richard Furman
Journal: Blood
Blood (2008) 112 (11): 5023.
https://doi.org/10.1182/blood.V112.11.5023.5023
Published: 2008
Journal Articles

Phase II Study of Forodesine, a PNP Inhibitor, in Patients with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia.

Ellen Ritchie, MD, Lia Gore, MD, Gail J. Roboz, MD, Eric Feldman, MD, Farhad Ravandi, MD, Richard Furman, MD
Journal: Blood
Blood (2006) 108 (11): 1881.
https://doi.org/10.1182/blood.V108.11.1881.1881
Published: 2006
Journal Articles

Prophylactic Low-Dose Aspirin Is Effective as Antithrombotic Therapy in Patients Receiving Combination Thalidomide or Lenalidomide.

Ruben Niesvizky, MD, Deborah M. Martinez-Banos, MD, Udi Y. Gelbshtein, Hearn J. Cho, MD, PhD, Roger N. Pearse, MD, PhD, Faiza Zafar, RPAC, Karen Pekle, NP, Richard Furman, MD, John P. Leonard, MD, Morton Coleman, MD
Journal: Blood
Blood (2005) 106 (11): 3454.
https://doi.org/10.1182/blood.V106.11.3454.3454
Published: 2005